SRNE News and Press, Sorrento Therapeutics Inc. From 12/20/21

The FDA has authorized Sorrento Therapeutics' (NASDAQ:SRNE) IND application for a phase 1b trial of STI-1386 (Seprehvec) for oncolytic virus in patients with relapsed or refractor solid tumors. "Seprehvec allows for locoregional immune stimulation at the tumor site while potentially mini...

SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the U.S. Food and Drug Administration (FDA) has granted clearance to proceed with a Phase 1b clinical trial using STI-1386, Seprehvec™, entitled “Dose Escal...

As early lab results on the vaccine effectiveness against the Omicron variant started to emerge, COVID-19 vaccine stocks led by BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) sank this week, dragging the NASDAQ Biotechnology Index (NASDAQ:IBB) for the second consecutive week. However, the h...

Sorrento Therapeutics' (SRNE) subsidiary Scilex Holding Company announces positive top-line results from its SP-102 (SEMDEXA) Phase 3 Trial C.L.E.A.R. Program, a corticosteroid injectable dexamethasone sodium phosphate viscous gel for the treatment of lumbosacral radicular pain, or sciat...

Scilex Holding Company, a commercial-stage, non-opioid biopharmaceutical pain management company, announces highly significant positive top-line results from its Phase 3 SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R Program for its novel, non-opioid, corticosteroid formulation, injecta...

A Phase 2 trial of intra-articular RTX for knee OA pain has enrolled its first two patients. The injections were well tolerated and both patients were discharged home after a brief period of observation. Phase 1b data demonstrated significant efficacy supporting RTX as an ideal ca...

SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Sorrento’s Clinical Laboratory, located in San Diego, California,...

Palm Beach, FL – December 7, 2021 – FinancialNewsMedia.com News Commentary There are many unknowns surrounding the new omicron Covid variant; there are early signs it’s more transmissible, but it’s not yet known what risks it poses to public health. G...

Shares of Sorrento Therapeutics (SRNE +6.0%) are modestly higher in afternoon trading after the company announced an order from a large diagnostic laboratory in Brazil for its COVISTIX COVID-19 test. The company said the tests will begin to be delivered by the end of the year. Sorrento says t...

Sorrento has received orders from its logistics partner and a large diagnostic laboratory client for official commercial launch of COVISTIX™ COVID-19 Virus Rapid Antigen Detection Test in Brazil. SAN DIEGO, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasd...